Facebook
X
LinkedIn
ForwardIntegrating Pharmacogenomics into Clinical Practice: Certificate Program Online Course
Access to this online course is available from the date of purchase until the course expires on April 5, 2029. Credit must be claimed within that time period.
Registration required to claim CME credit.
Course Directors: Nick Nicholson, M.D., Pharm.D., Christopher Grilli, Pharm.D., R.Ph., M.B.A., Jennifer Bold, APRN, C.N.P., D.N.P., Denise Dupras, M.D., Ph.D.
Pharmacogenomics (PGx) explores how genes affect medication response. Mayo Clinic offers an online certificate for pharmacists, physicians, nurses, and students to integrate PGx into practice. The course includes 16+ hours of flexible, engaging content with 50+ videos and case studies. Learners earn a certificate and CME credit.
Target Audience
This activity has been designed for pharmacists, physicians, nurse practitioners, physician assistants, nurses, students, and other members of the healthcare team.
Learning Objectives
- Recognize foundational pharmacogenomics principles.
- Identify what to consider when implementing pharmacogenomics in clinical practice.
- Recognize pharmacogenomics test results to make recommendations for an individualized medication management plan.
- Identify barriers and challenges of considering pharmacogenomics in patient care.
Utilization of this Mayo Clinic online (enduring materials) course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be in this course.
Additional Information
| Attachment | Size |
|---|---|
 Additional Information | 204.23 KB |
| Integrating Pharmacogenomics into Clinical Practice: Certificate Program Online Course | ||
| April 6, 2026 - April 5, 2029 | ||
| Duration | Lecture Title | Speaker(s) |
| 0:02:01 | Introduction video to start course | Christopher T. Grilli, Pharm.D., R.Ph., M.B.A. |
| 0:08:31 | Race to the Starting Line video | Richard Weinshilboum, M.D. |
| Pharmacogenomics: Principles and Concepts | ||
| 0:17:43 | Pharmacogenomics 101: An Introduction to Foundational Concepts | Christopher T. Grilli, Pharm.D., R.Ph., M.B.A. |
| 0:21:45 | Variability and Pharmacokinetic Principles | Wayne T. Nicholson, M.D., Pharm.D. |
| 0:40:49 | Sex, Drugs, and Genetic Variation | Ann M. Moyer, M.D., Ph.D. |
| 0:27:09 | Pharmacogenomics’ Emerging Role | Richard Weinshilboum, M.D. |
| 0:27:14 | Pharmacogenomics: Discovery and Translation | Liewei Wang, M.D., Ph.D. |
| 0:19:24 | Untangling the Polypharmacy Burden with Pharmacogenomics Testing | Eric T. Matey, Pharm.D., R.Ph. |
| Pharmacogenomics: Rules and Regulations | ||
| 0:10:30 | Legal Implications of Pharmacogenomics Testing | AnJuanna A. Robinson, J.D. |
| 0:08:29 | PGx from a Patient Perspective: GINA & Other Important Questions | Teresa M. Kruisselbrink, M.S., CGC, LCGC |
| Pharmacogenomics: Clinical Laboratory Testing | ||
| 0:22:56 | Clinical Laboratory Testing in PGx: “the Lab” 101 | Ann M. Moyer, M.D., Ph.D. |
| 0:29:42 | Clinical Laboratory Testing in PGx: Targeting Genotyping Technology | Ann M. Moyer, M.D., Ph.D. |
| 0:26:39 | Clinical Laboratory Testing in PGx: “Sequencing” | Ann M. Moyer, M.D., Ph.D. |
| 0:26:07 | Clinical Laboratory testing in PGx: “Reporting” | Ann M. Moyer, M.D., Ph.D. |
| Pharmacogenomics in Practice: General Principles | ||
| 0:22:25 | Pharmacogenomics Testing: Role in Clinical Medicine | Denise M. Dupras, M.D., Ph.D. |
| 0:19:19 | 10 Considerations for the Clinician Applying Pharmacogenomics to Practice | Wayne T. Nicholson, M.D., Pharm.D. |
| 0:29:48 | Polypharmacy and PGx: Multi-Drug, Herbal/Dietary Supplement Case Study | Michael J. Schuh, Pharm.D., R.Ph. |
| 0:23:31 | Utilizing National Pharmacogenomics Guidelines and Other Resources | Jessica A. Wright, Pharm.D., R.Ph. |
| 0:23:59 | Case Review: From My Practice to Yours | Sheena K. Crosby, Pharm.D., R.Ph. |
| Pharmacogenomics in Practice: Panel Discussions | ||
| 0:21:24 | Pharmacogenomics from the Clinician Perspective | Matthew E. Bernard, M.D. Jennifer A. Bold APRN, C.N.P., D.N.P. Darryl S. Chutka, M.D. (Moderator) Paul Y. Takahashi, M.D. |
| 0:18:10 | Pharmacogenomics from the Pharmacy Perspective | Christopher Grilli, Pharm.D., R.Ph.,M.B.A. (Moderator) Ashley D. Ebenhoh, Pharm.D., R.Ph. Razan M. El Melik, Pharm.D., R.Ph. |
| Pharmacogenomics in Practice: Analgesic/Anesthesia | ||
| 0:20:35 | Pharmacogenomics of Analgesics | Wayne T. Nicholson, M.D., Pharm.D. |
| 0:15:43 | Pharmacogenomics: Anesthesia | Timothy B. Curry, M.D., Ph.D. |
| Pharmacogenomics in Practice: Psychiatry: Panel Discussion | ||
| 0:43:43 | Psychiatric Pharmacogenomics | Darryl S. Chutka, M.D. (Moderator) Eric T. Matey, Pharm.D., R.Ph. Denise M. Dupras, M.D., Ph.D. Richard Weinshilboum, M.D. |
| Pharmacogenomics in Practice: Cardiology/GI | ||
| 0:24:17 | Pharmacogenomics in Cardiovascular Disease | Linnea M. Baudhuin, Ph.D. |
| 0:15:16 | Warfarin & Statin Pharmacogenomics Cases | Jan A. Anderson, Pharm.D., R.Ph. |
| 0:18:26 | PGx use in Patients with Gastroesophageal Reflux Disease | Imad Absah, M.D. |
| Pharmacogenomics in Practice: Oncology/Hematology | ||
| 0:25:33 | Pharmacogenomics in Oncology | Eric J. Yancey, Pharm.D., R.Ph. |
| 0:28:12 | Why is CYP2D6 Genotyping Ready for Primetime: Association of CYP2D6 Genotype and Breast Cancer Outcome from Large Trials | Matthew P. Goetz, M.D. |
| 0:32:28 | Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Implications for 5-Fluorouracil (Capecitabine) Treatment | Robert B. Diasio, M.D. |
| 0:12:29 | Belinostat and UGT1A Polymorphism | N. Nora Bennani, M.D. |
| 0:22:45 | Case: Oncology | Caren L. Hughes, Pharm.D., R.Ph. |
| 0:11:19 | Case Study: Thiopourines/TPMT and NUDT15 in Clinical Practice | Edward V. Loftus, Jr. M.D. |
| Pharmacogenomics in Practice: Transplant, Infectious Disease, Immunology, Urology | ||
| 0:14:17 | Pharmacogenomics for Transplant Patients: Immunosuppression and Beyond | Mira T. Keddis, M.D. |
| 0:07:54 | Pharmacogenomics: Challenges with Hematopoietic Stem Cell and Liver Transplantation | John Logan Black, M.D. |
| 0:09:49 | Voriconazole | Christopher J. Arendt, Pharm.D., R.Ph. |
| 0:19:41 | Using Pharmacogenomics to Predict Drug Hypersensitivity | John D. Zeuli, Pharm.D., R.Ph. |
| 0:09:40 | HLA and Hypersensitivity | Jyothsna (Jo) Giri, M.D., M.B.A. |
| 0:11:54 | Gout Management: Role of Pharmacogenomics | Denise M. Dupras, M.D., Ph.D. |
| Pharmacogenomics Implementation | ||
| 0:18:15 | Significant Pharmacogenomics Cases | Heather H. Randles, Pharm.D., R.Ph. |
| 0:08:57 | Developing an Individualized Medication Plan | Eric T. Matey, Pharm.D., R.Ph. |
| 16:13:16 Content Hours | ||
| 16.00 Credit Hours | ||
Course Director(s):
Nick Nicholson, M.D., Pharm.D.
Christopher Grilli, Pharm.D., R.Ph., M.B.A.
Jennifer Bold, APRN, C.N.P., D.N.P.
Denise Dupras, M.D., Ph.D.
Mayo Faculty:
AnJuanna A. Robinson, J.D.
Ann M. Moyer, M.D., Ph.D.
Ashley D. Ebenhoh, Pharm.D., R.Ph.
Caren L. Hughes, Pharm.D., R.Ph.
Christopher J. Arendt, Pharm.D., R.Ph.
Christopher T. Grilli, Pharm.D., R.Ph., M.B.A.
Darryl S. Chutka, M.D.
Denise M. Dupras, M.D., Ph.D.
Edward V. Loftus, Jr., M.D.
Eric J. Yancey, Pharm.D., R.Ph.
Eric T. Matey, Pharm.D., R.Ph.
Heather H. Randles, Pharm.D., R.Ph.
Imad Absah, M.D.
Jan A. Anderson, Pharm.D., R.Ph.
Jennifer A. Bold, APRN, C.N.P., D.N.P.
Jessica A. Wright, Pharm.D., R.Ph.
John D. Zeuli, Pharm.D., R.Ph.
John Logan Black, M.D.
Liewei Wang, M.D., Ph.D.
Linnea M. Baudhuin, Ph.D
Matthew E. Bernard, M.D.
Matthew P. Goetz, M.D.
Michael J. Schuh, Pharm.D., R.Ph.
Mira T. Keddis, M.D.
N. Nora Bennani, M.D.
Paul Y. Takahashi, M.D.
Razan M. El Melik, Pharm.D., R.Ph.
Richard Weinshilboum, M.D.
Robert B. Diasio, M.D.
Sheena K. Crosby, Pharm.D., R.Ph.
Timothy B. Curry, M.D., Ph.D.
Nick T. Nicholson, M.D., Pharm.D.
Guest Faculty:
Teresa M. Kruisselbrink, M.S., CGC, LCGC
Jyothsna (Jo) Giri, M.D., M.B.A.
Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
AMA
Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 16.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE
Mayo Clinic College of Medicine and Science designates this educational activity for a maximum of 16.00 Knowledge-based contact hours. Participants should claim only the credit commensurate with the extent of their participation in the activity. UAN Number: JA0000238-0000-26-091-H04-P
ANCC
Mayo Clinic College of Medicine and Science designates this activity for a maximum of 16.00 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals
A record of attendance will be provided to all registrants for requesting credits in accordance with state nursing boards, specialty societies or other professional associations.
For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.
Available Credit
- 16.00 ACPE
- 16.00 AMA PRA Category 1 Credit™
- 16.00 ANCC
- 16.00 Attendance
Price
Access to this online course is available from the date of purchase until the course expires on April 5, 2029. Credit must be claimed within that time period.
Registration required to claim CME credit.
Commitment to Belonging and Inclusion
Mayo Clinic School of Continuous Professional Development (MCSCPD) strives to foster a learning environment in which all individuals are valued, allowing all to achieve their fullest potential.
Every effort will be made to accommodate dietary requirements; however, some requests may not be feasible based on venue kitchen capabilities. Attendees will be contacted in advance if a dietary restriction cannot be fulfilled.
The Mayo Clinic School of Continuous Professional Development strives for fully accessible learning experiences. If you anticipate any barriers while attending this course, please reach out to the course coordinator who will be in touch with all registrants. If you need disability-related accommodations, please contact the Office of Wellness and Academic Support – Disability Access Services at MCCMS.DS@mayo.edu.
Cancellation and Refund Policy
View Cancellation and Refund Policy
All requests must be submitted in writing using the Contact Us Form.
Any use of this site constitutes your agreement to the Terms and Conditions of Registration.